surpass tirzepatide SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS-CVOT shows tirzepatide delivers comparable

While no differences in the risk of HSV or HZ infections were observed between GLP-1RA and SGLT-2i in patients with HbA1c 7%, the significantly increased risk of HSV infections associated with GLP-1RA compared to DPP-4i underscores the need for periodic monitoring

Most side effects resolve within 4-6 weeks as your body adjusts

Organizations increasingly seek strategic partnerships that provide access to high-purity compounds and dependable fulfillment capabilities

95% CI, 0.511.00) and all-cause mortality (adjusted pooled HR, 0.68

Ozempic, generically known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist that was initially developed for the treatment of type 2 diabetes